Premium
Fine needle aspiration biospy or not?
Author(s) -
Cassoux N.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0184
Subject(s) - medicine , biopsy , fine needle aspiration , histopathology , metastasis , sampling (signal processing) , radiology , surgery , pathology , cancer , filter (signal processing) , computer science , computer vision
Summary Thanks to the dramatic progress in the field of ophthalmic surgery (mini invasive surgery), sampling an eye is more and more used in ocular tumors. A biopsy can be done via a transcleral or transvitreal route to diagnosed difficult cases especially achromic ocular tumors. However, fine needle aspiration biopsy or biopsy with a vitrector handpiece is more and more used to stratified uveal melanoma patients into low risk, intermediate risk, and high risk of metastasis using genomic (using a‐CGA or MLPA) or gene expression profile (GEP). The biopsy can be done before irradiation or the last day of irradiation or after irradiation (during an endoresection of the tumor). Large series have shown that the procedure is safe and efficient. The main issue is to deal with the results since we don't have to date an effective treatment for metastatic patients. However, tumor prognostication is important to develop because there is a learning curve for surgeon and to establish a good collaboration with the histopathology or genetic laboratories and new molecules are in the pipe (targeted therapies, immunotherapies) to treat metastatic patients in a close future.